Skip to main content

NCI-H441 Transfection Reagent (Lung Adenocarcinoma)

The NCI-H441 cell line was discovered in 1982, and derived from the pericardial fluid of a male patient suffering from papillary adenocarcinoma. The cells express both major surfactant apoprotein (SP-A) and pulmonary surfactant protein (SP-B) with a doubling time of roughly 58 hours. The biomedical application of NCI-H441 widely ranges however its primary use is in lung cancer research. Altogen Biosystems provides a transfection reagent for NCI-H441 that optimizes the transfection efficiency. 

Transfection Reagent for NCI-H441 Cells (Lung Adenocarcinoma Cells, HTB-174)
Labels:

Popular posts from this blog

NCI-H441 Cells for Lung Cancer Discoveries

NCI-H441 cells were derived from the papillary adenocarcinoma of a human male patient and constitute an epithelial cell line that is one of the foremost models researchers have for investigating the efficacy of inhalant-based cancer therapies. With delivery to the lungs much easier through airways in the human body, novel treatments may focus on delivering nucleic acids in non-cytotoxic transfection reagents to alveoli and other lung cells. NCI-H441 cells are known for doubling in population size under sixty hours, and express the major surfactant apoprotein, making them a unique environment for drug testing, lung cancer research, and siRNA screening for the development of gene therapies targeting late-stage lung cancer.
Post a Comment
Read more